| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
Jemal A, Bray F, Center MM, et al. Global cancerstatistics[J]. CA A Cancer J Clin, 2011, 6(2): 169-190.
|
| 3 |
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021, PMID: 33818764
|
| 4 |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA: A Cancer J Clin, 2021, 71(1): 7-33.
|
| 5 |
杨 洋，隋铁泉. 肺癌围手术期免疫功能保护的研究进展[J]. 现代肿瘤医学，2020, 28(3): 512-516.
|
| 6 |
Chen FF, Zhang D, Wang YL, et al. Video-assisted thoracoscopic surgery lobectomy versus open lobectomy in patients with clinical stage Ⅰ non-small cell lung cancer: A meta-analysis[J]. Eur J Surg Oncol, 2013, 39(9): 957-963.
|
| 7 |
Handy JR, Asaph JW, Charles DE, et al. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy？[J]. Eur J Cardiothorac Surg, 2010, 37(2): 451-455.
|
| 8 |
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017, 15(4): 504-535.
|
| 9 |
Howington JA, Blum MG, Chang AC, et al. Treatment of stage Ⅰ and Ⅱ non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(5 Suppl): e278S-e313S.
|
| 10 |
Vallejo R, Hord ED, Barna SA, et al. Perioperative immunosuppression in cancer patients[J]. J Environ Pathol Toxicol Oncol, 2003, 22(2): 139-146.
|
| 11 |
Battershill AJ, Keating GM. Remifentanil: A review of its analgesic and sedative use in the intensive care unit[J]. Drugs, 2006, 66(3): 365-385.
|
| 12 |
盛娅仪，徐振邦. 瑞芬太尼的药理学和临床应用[J]. 中国新药与临床杂志，2001, 20(2): 142-146.
|
| 13 |
Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis c virus infection related to a growing opioid epidemic and associated injection drug use, united states, 2004 to 2014[J]. Am J Public Health, 2018, 108: 175-181.
|
| 14 |
Kisilewicz M, Rosenberg H, Vaillancourt C. Remifentanil for procedural sedation: a systematic review of the literature.[J]. Emergency Medicine Journal, 2017, 34(5): 294-301.
|
| 15 |
Hannam JA, Borrat X, Troconiz IF, et al. Modeling respiratory depression induced by remifentanil and propofol during sedation and analgesia using a continuous noninvasive measurement of pCO2[J]. J Pharmacol Experiment Therapeut, 2015, 356(3): 563-573.
|
| 16 |
张素玲，刘婷婷，靳茜茜，等. 影响恶性肿瘤手术患者围术期免疫功能的因素[J]. 医学综述，2017, 23(11): 2176-2180.
|
| 17 |
Ramirez MF, Ai D, Bauer M, et al. Innate immune function after breast, lung, and colorectal cancer surgery[J]. J Surg Res, 2015, 194(1): 185-193.
|
| 18 |
王天佑，李单青，崔 永，等. 胸外科围手术期肺保护中国专家共识(2019版)[J]. 中国胸心血管外科临床杂志，2019, 26(9): 835-842.
|
| 19 |
李秋兰，徐振华，高艳平，等. 不同浓度瑞芬太尼辅助麻醉对肺癌根治术患者围术期免疫功能的影响[J]. 广西医科大学学报，2019, 36(4): 86-90.
|
| 20 |
张国庆. 右美托咪定复合瑞芬太尼用于肺癌切除术后的镇痛效果及对机体免疫功能的影响[J]. 中国药房，2016, (27): 4215-4217.
|
| 21 |
Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells[J]. Nature, 1995, 378(6552): 88-91.
|
| 22 |
李 琼，郭善亮，杨 力，等. 瑞芬太尼术后镇痛对肿瘤患者T淋巴细胞亚群的影响[J]. 临床麻醉学杂志，2011, 27(10): 991-992.
|
| 23 |
谭周鹏. 不同浓度瑞芬太尼辅助麻醉对肺癌根治术患者围术期免疫功能的影响[J]. 临床研究，2020, 28(7): 42-44.
|
| 24 |
刘东海. 靶控输注舒芬太尼或瑞芬太尼用于妇科腹腔镜手术麻醉的效果比较[J]. 现代中西医结合杂志，2016, 25(20): 2264-2265+2270.
|
| 25 |
黄 洪，杨荣焕，凌 玲. 内科胸腔镜对胸膜腔病变的应用价值[J]. 中国医药科学，2018, 8(15): 182-184，215.
|